$VCYT News

Veracyte, Inc. 2026 Q2 - Results - Earnings Call Presentation

Needham Maintains Buy on Veracyte, Raises Price Target to $69

Veracyte, Inc. (VCYT) Q2 2026 Earnings Call Transcript

Veracyte (NASDAQ:VCYT) Smashes Q2 Estimates but Full-Year Guidance Disappoints, Shares Fall

Veracyte Raises FY2026 Sales Guidance from $582.000M-$592.000M to $590.000M-$596.000M vs $586.445M Est

Veracyte Inc (NASDAQ:VCYT) Shows a High Growth Momentum Breakout Setup Near Resistance

Veracyte Inc (NASDAQ:VCYT): A High Growth Stock With a Strong Technical Breakout Setup

Piper Sandler Initiates Coverage On Veracyte with Overweight Rating, Announces Price Target of $66

Canaccord Genuity Maintains Hold on Veracyte, Raises Price Target to $60

Morgan Stanley Maintains Underweight on Veracyte, Raises Price Target to $47

Veracyte Inc (NASDAQ:VCYT) Fits the Affordable Growth Profile

Guggenheim Maintains Buy on Veracyte, Raises Price Target to $65

High Growth Momentum Breakout Setup: Veracyte Inc (NASDAQ:VCYT)

How Veracyte (VCYT) Investors Can Read The Latest Unchanged Analyst Call

Veracyte, Inc. (VCYT) Discusses ASCO Findings From OPTIMA and ENZAMET Phase III Trials in Breast and Prostate Cancer - Slideshow

Veracyte, Inc. (VCYT) Presents at 46th Annual William Blair Growth Stock Conference - Slideshow

Veracyte, Inc. (VCYT) Discusses ASCO Findings From OPTIMA and ENZAMET Phase III Trials in Breast and Prostate Cancer Transcript

Veracyte Announces Commercial Launch of the Prosigna Breast Test in the U.S.

Needham Maintains Buy on Veracyte, Raises Price Target to $57

Veracyte Commercially Rolls Out Prosigna Breast Risk Of Recurrence Test Across U.S.